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RadionecrosisPeriventricular heterotopia (PVH) is a neuronal migration disorder characterized by masses of gray matter
located along the lateral ventricles that commonly cause epilepsy. The beneﬁt of surgical resection of the
PVH has been demonstrated in case reports to date; however, the location of the PVH in the paratrigonal
region of the lateral ventricles can present signiﬁcant surgical challenges. Noninvasive modalities of ablating
this epileptogenic focus must therefore be considered. We present a small series of three patients who
underwent stereotactic radiosurgery (SRS) for inoperable unilateral dominant hemisphere PVHs in order to
illustrate the potential beneﬁts and risks of this treatment modality. A total dose of 37.5–65 Gy resulted in
seizure freedom for at least 14 months at the time of their last follow-up, even in patients harboring a second
independent epileptic focus. Whether intracranial electrode recording truly offers added value is therefore
uncertain. The two patients who received higher radiation doses suffered from symptomatic radiation necrosis
and associated cerebral edema, requiring further medical intervention, and persistent monocular visual loss in
one patient.While a longer interval prior to re-treatmentmay have been attempted, neither patient demonstrated
radiographic ﬁndings typically associatedwith seizure remission. Refractory epilepsy due to PVHmay be success-
fully treatedwith radiation therapy; but further work is needed to deﬁne the optimal dosing parameters in order
to lower toxicity to normal tissue.
© 2012 The Authors. Published by Elsevier Inc.Open access under CC BY license.1. Introduction
Periventricular heterotopia (PVH) is a neuronal migration disor-
der characterized by masses of gray matter located along the lateral
ventricles in varying distribution. Although the clinical symptoms
in these patients can vary, the most common presentation of PVH
cases is epilepsy [1–3]. Clinical and electrographic ﬁndings pointing
to a temporal lobe focus in PVH patients have been misleading and
have consequently generated poor surgical results in patients who
have undergone temporal lobectomy [4]. While more recent studies
have shown improved surgical outcome following more speciﬁc
localization of the epileptogenic focus, no studies have shown the+1 888 377 9534.
g (C. Wu).
nc.Open access under CC BY license.use of stereotactic radiosurgery (SRS) as an alternative to surgical
resection [5]. Here, we present a small series of three patients who
underwent SRS for unilateral dominant hemisphere PVH. All had
been deemed inoperable due to risks of causing aphasia. These
cases illustrate the potential beneﬁts and risks of this treatment
modality.2. Materials and methods
A retrospective chart review was performed on three patients
who presented to our institution with medically-refractory epilepsy
secondary to a dominant hemisphere PVH. Patients were treated
with SRS between 2003 and 2009 by a multidisciplinary team
consisting of epileptologists, radiation oncologists, and neurosur-
geons. If a patient continued to experience seizures after a single
treatment, a consensus decision was made to administer a second
dose of radiation, resulting in a total dose range of 37.5–65 Gy in
this series. Follow-up continued until 2011, allowing seizure and
complication rates to be recorded over periods ranging from 33 to
46 months.
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3.1. Case 1
3.1.1. Seizure history
A 25-year-old right-handed femalewith no preexisting epilepsy risk
factors and no signiﬁcant pastmedical history began experiencing com-
plex partial seizures at age 14. Her seizures were preceded by an aura
that she described as a “feeling of fading away" or “feeling like blacking
out and feeling confused.” Witnessed episodes consisted of lip smack-
ing, chewing, and oral automatisms accompanied by an impaired level
of consciousness with an inability to talk or follow commands. Seizures
occurred once to twice each week. Medical treatment with carbamaze-
pine, levetiracetam, phenobarbital, and oxcarbazepine failed to control
seizures.3.1.2. Evaluation
Scalp video-EEG monitoring demonstrated left midtemporal
interictal sharp waves, and seizures began focally with left sphenoidal
sharp waves followed by postictal slowing in the left hemisphere. On
neuropsychological testing, she demonstrated a verbal IQ of 102, per-
formance IQ of 104, full scale IQ of 104 and Boston naming score of 44.
Additionally, she had weakness in word knowledge, impaired verbal
learning, working memory, and facial memory. MRI demonstrated
an 8-mm periventricular heterotopia adjacent to the left trigone andFig. 1. A: T1 MRI demonstrating PVH in the left trigone. B: T2 Coronal MRI status-post impla
trigone PVH.associated left mesial temporal sclerosis (Fig. 1A). PET scan showed
decreased metabolic activity in the left inferior temporal lobe.
The patient underwent invasive monitoring. Depth electrodes
were implanted into the parahippocampus, anterior, middle, and pos-
terior hippocampus; a depth electrode was placed in the heterotopia
as well. Four strip electrodes were placed over temporal neocortex
(Fig. 1B). Video-EEG recordings revealed seizures that began in the
heterotopia and then spread to the hippocampus within 10 s.
Interictal spikes were also evident in the heterotopia, hippocampus
and temporal basal cortex.3.1.3. Treatment and follow-up
Because of its location and the inherent risks of surgical resection
in the dominant posterior temporal lobe, Gamma Knife Radiosurgery
(GKR) was recommended. The ﬁrst treatment occurred two months
after intracranial electrode placement. A dose of 30 Gy was delivered
to a 50% isodose line with three shots (Fig. 1C). Unfortunately, she
continued to experience seizures at 12-month follow-up and an MRI
revealed no lesional changes in the PVH (Fig. 1D). Her seizure activity
had changed from one seizure per week to a cluster of 2–9 seizures
within 1–2 days that occurred every 2–3 weeks. Therefore, the pa-
tient was treated with additional GKR 15 months after the initial
treatment. A dose of 35 Gy was prescribed to a 50% isodose line with
three shots to a lesion volume of 0.27 cc. The patient has been seizure
free for 78 months since the second treatment and stopped medicationntation of intracranial electrodes. C: Dose plan for Case 1. D: Axial T2 MRI showing left
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either clinically or in post-treatment scans.
3.2. Case 2
3.2.1. Seizure history
A 26-year-old female began experiencing tonic-clonic seizures at
age 21. Her risk factors for epilepsy included premature birth at
35 weeks gestation, learning disability, and mild mental retardation.
Her seizures were initially well controlled on phenytoin; but unfortu-
nately, eight months after initial medical treatment she began havingFig. 2. A: Coronal T2 MRI showing left trigone PVH. B: CT scan demonstrating cerebral edem
plan for second LINAC treatment for Case 2.complex partial seizures preceded by an aura of dizziness. Zonisamide,
lamotrigine, oxcarbazepine, and levetiracetam all failed to control her
seizures. Her longest seizure-free interval was 17 days with these
medications.
3.2.2. Evaluation
Scalp video-EEG demonstrated a left sphenoidal onset of seizures
with 5- to 6-Hz activity and left sphenoidal interictal sharp waves.
Brain MRI revealed a PVH adjacent to the trigone of the left lateral
ventricle and left mesial temporal sclerosis (Fig. 2A). Depth electrodes
were placed in the left hippocampus and heterotopia; left temporala from radiation necrosis. C: Dose plan for initial LINAC treatment for Case 2. D: Dose
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with these intracranial electrodes revealed independent seizure on-
sets zones in the heterotopia as well as in the left temporal neocortex.
Depending on the site of onset, ictal spread occurred within 1 s be-
tween these two regions. Interictal spikes in the heterotopia, left hip-
pocampus, and temporal neocortex were also noted.
3.2.3. Treatment and follow-up
Due to the location of the heterotopia and the risks of surgical resec-
tion, linear accelerator (LINAC) radiosurgery to the heterotopias was
recommended. A dedicated stereotactic LINAC (BrainLab Inc, Munich,
Germany) was used for treatment with dynamic conformal arcs meth-
odology. The ﬁrst treatment occurred 8 months after invasive monitor-
ing and consisted of a dose of 21 Gy delivered to a 92% isodose line,
covering 98% of the lesion (Fig. 2C). Seizures continued and she began
to experience an increased seizure frequency. Follow-up imaging dem-
onstrated no radiation effect and the patient therefore underwent a sec-
ond treatment session 10 months after initial treatment. This time,
40 Gy was administered to a 91% isodose line covering 100% of the le-
sion — measuring 2.21 cc (Fig. 2D). Seizure frequency decreased over
the next 6 months with a three-month seizure-free period. She was
maintained on pre-treatment doses of oxcarbazepine and levetiracetam.
Her post-treatment course was then complicated by intermittent
headaches, a mild expressive aphasia, facial edema, papilledema,
and slight hyperesthesia in the left V2 distribution that began
7 months following the second LINAC treatment. A CT scan of her
brain demonstrated left-sided cerebral edema, for which she was
placed on steroids (Fig. 2B). MRI revealed a ring-enhancing lesion
consistent with radionecrosis. As she was initially weaned from her
steroids, she experienced a recurrence of her symptoms and required
hospitalization and reinstitution of a steroid regimen. She had visual
deterioration to acuity of 20/70 and optic nerve sheath fenestration
was performed. After recovering from this second episode, she has
been seizure free for 54 months at the time of last follow-up. Vision
completely recovered in one eye and remained impaired in the other.
3.3. Case 3
3.3.1. Seizure history
A 27-year-old right-handed male with no seizure risk factors devel-
oped complex partial seizures at age 20. He characterized these seizures
as startingwith an aura of dizziness with ensuing loss of awareness and
confusion. During these episodes, he spoke intelligently but did not fol-
low commands or recall the events. He reported clusters of 3 to 4Fig. 3. A: Post-operative coronal T1 MRI showing depth electrodes. B: Dose plan for Caseizures per week, which occurred approximately every 2 months. At
the time of admission, his seizures had been shown to be refractory to
prior treatment with oxcarbazepine and was taking both topiramate
and levetiracetam.
3.3.2. Evaluation
Scalp video-EEG demonstrated frequent interictal left temporal
lobe slowing and sharp waves. Complex partial seizures began with
8-Hz activity originating at T5. Imaging studies included an MRI con-
sistent with PVH involving the left lateral ventricle in the trigone and
region of the occipital horn (Fig. 3A).
Intracranial video-EEG conﬁrmed that the heterotopia was the lo-
cation of seizure onset for some seizures, but also demonstrated some
seizures appeared to start simultaneously in the overlying temporal
lobe neocortex. Similarly, the interictal EEG demonstrated spikes in
the heterotopia, neocortex and hippocampus.
3.3.3. Treatment and follow-up
As with the prior two cases, it was decided that the best modality of
treatmentwas SRS. Twomonths after localization via invasivemonitor-
ing, he was treated with 37.5 Gy GKR delivered to a 50% isodose line,
covering 100% of the lesion, which measured 0.5 cc in volume
(Fig. 3B). He had no seizures for the ﬁrst six months after treatment,
at which time his seizures recurred at a rate of 1–3 seizures per month.
Nineteen months after GKR treatment, he developed severe head-
aches without a focal neurologic deﬁcit. A CT scan and subsequent
MRI demonstrated lateralized cerebral edema consistent with radia-
tion necrosis (Fig. 3C). He was treated with a course of steroids and
maintained on topiramate and levetiracetam. At the time of last
follow-up, approximately 33 months after his treatment, he had
been seizure free for 14 months and continued to take topiramate
and levetiracetam.
4. Discussion
While structural features in patients with PVH may vary, they
share a central theme of drug-resistant epilepsy. Clinical presenta-
tions and surface EEG pointing to mesial temporal lobe origins have
been demonstrated to be misleading, and traditional temporal lobe
resection for these patients has resulted in poor outcomes. Such re-
sults are most likely due to incorrect localization — with seizures ac-
tually originating from the PVH [5,6]. Improper localization may stem
from the connections of the PVH to surrounding allocortex and neo-
cortex, which ampliﬁes its epileptic activity and leads to temporalse 3. C: Axial FLAIR MRI at 19 months post-treatment showing radiation necrosis.
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zures [5,6].
Further evidence of the importance of diagnosing a PVH is the
beneﬁt shown in case reports of surgical resection of the lesion.
Aghakhani described a good outcome (Engel Class ID) in a patient
with an epileptogenic focus conﬁned to the occipital neocortex who
underwent a transcortical occipital approach for the removal of two
nodules and a small rim of overlying cortex. Although a focal lesion
remained at a ﬁve-year follow-up, the patient required only a single
antiepileptic drug. Scherer et al. similarly reported a patient with a
PVH adjacent to the posterior horn of the left lateral ventricle, who
underwent a resection of this lesion and subsequently achieved sei-
zure freedom for 2 years [7]. In both cases, depth electrodes localized
seizure onset to the PVH and not in the hippocampus. These results
align with the current philosophy of epilepsy surgery — that good
outcomes occur when a single seizure generator can be localized
and resected [8–10].
In two of our patients, however, invasive monitoring indicated
two independent zones of ictal onset: the PVH and the temporal
lobe neocortex. While our suspicion of the PVH as the primary seizure
generator led us to target that lesion, we also planned for the possibil-
ity of a later cortical resection. Dosing plans were restricted to the
PVH alone and did not expose the relatively distant secondary ictal
onset zones to any signiﬁcant radiation (Figs. 1C, 2C, D, 3B). It is
therefore highly unlikely that any clinical effects may be attributed
to the inadvertent involvement of those separate seizure onset
zones in the treatment plan. These results contrast the aforemen-
tioned literature regarding the importance of a single focus of
epileptogenesis, since treating the PVH alone was effective in this
small series.
The location of a PVH can present signiﬁcant surgical challenges
with increased morbidity and mortality in patients [6]. Unilateral
PVH is frequently located in the paratrigonal region of the lateral ven-
tricles [10], where surgical resection is challenging due to intervening
and adjacent eloquent cortex — particularly in the dominant hemi-
sphere. For this reason, different modalities for ablating this epilepto-
genic focus must be considered.
All three of our patients harbored a unilateral left dominant PVH
that was identiﬁed as a seizure onset zone. Therefore, in light of the
success of SRS in patients with epilepsy of other underlying etiologies
[3,11–32], this less invasive modality was chosen. Patients with epi-
lepsy attributable to hypothalamic hamartomas have successfully un-
dergone radiosurgery with dosages of 12–20 Gy [12,13]. Similarly,
Regis reported a 60% seizure-free outcome with >5 year follow-up
in 9 of 16 patients who underwent 24 Gy of GKR for mesial temporal
lobe epilepsy (MTLE) [3]. Although doses ranging from 18 to 25 Gy
have been reported in the treatment of MTLE [3,15–32], doses of
20 Gy and 24 Gy have been extensively studied, with long-term out-
comes of >60% seizure freedom associated with both dosages
[17,18,29]. We are well aware that the dosages presented here are
signiﬁcantly higher than those reported in the literature to date. The
ﬁrst two patients received comparable initial radiation doses of 21–
30 Gy; but when this treatment failed to provide adequate seizure
control, re-treatment increased the total dose exposure to 61–
65 Gy. While Case 1 demonstrated a favorable outcome after 65 Gy
of exposure, Case 2 suffered signiﬁcant morbidity from 61 Gy. InTable 1
Summary of treatment courses for 3 patients with periventricular nodular heterotopia.
Patient Location of seizure focus Volume [cc] SRS
modality
Initial dose [Gy]
Case 1 Heterotopia 0.27 GKR 30.0
Case 2 Heterotopia & left temporal lobe 2.21 LINAC 21.0
Case 3 Heterotopia & left temporal lobe 0.50 GKR 37.5light of the complications encountered in Case 2, the initial radiation
dose was reduced to 37.5 Gy for Case 3 (Table 1).
Indeed, higher doses of radiation have been associated with com-
plications secondary to radiation necrosis and associated cerebral
edema [24]. In his experience with 23 patients, Regis reported four
cases of visual ﬁeld defects and three cases of morbidity requiring
corticosteroids for radiation-induced changes [11,14,15]. While corti-
costeroids are typically sufﬁcient to reduce such edema [14–17,31],
some patients have required surgical decompression [20]. Unfortu-
nately, one of our patients shared a similar fate, requiring optic
nerve sheath fenestration and suffering from a permanent monocular
visual deﬁcit.
Although Case 3 also demonstrated radiographic ﬁndings of radia-
tion necrosis and associated cerebral edema (Fig. 3C), this ﬁnding
only manifested clinically as headaches. In fact, noticeable radiation
changes may be necessary to achieve a therapeutic effect. Chang et
al. reported that the appearance of vasogenic edema 9–12 months
after treatment correlated with the onset of seizure remission [29].
Similarly, Rheims et al. noted that subnecrotic radiation-induced tis-
sue changes might contribute to the antiepileptic effect of GKR. The
optimal dose should therefore induce these necessary changes while
avoiding adverse clinical symptoms.
Finding this therapeutic range for radiation to a PVH is complicat-
ed by the inability to use MRI alone to assess the effects of treatment.
Radiation-induced changes in MRI have been found to vary even
when doses have been standardized [29]. Therefore, the use of pro-
ton (1H) magnetic resonance spectroscopy (MRS) may be helpful
in further characterizing the speciﬁc effects of radiation. As with
MRI, radiographic changes in MRS have been reported to peak
approximately one year after radiation [32]. Speciﬁcally, radiation
necrosis has been characterized by a decrease in N-acetylaspartate
(NAA), creatine (Cr), and choline (Cho) peaks; but an increase in
the lactate peak [31–34]. Furthermore, the severity of injury has
been associated with greater reductions of N-acetylaspartate (NAA)
than creatine (Cr), which itself has declined more than choline
(Cho). This results in low NAA/Cho and NAA/Cr ratios, but a high
Cho/Cr ratio [31–33]. In addition, higher lactate/Cr ratios have been
associated with more extensive mass effect changes [34]. Further
work must be performed in order to determine if speciﬁc values
can be correlated with therapeutic effects. Unfortunately, since
none of our patients underwent MRS after radiation, we are unable
to help in this endeavor.
Given the small sample size of three patients in this series,
recommending an ideal dose of radiation remains difﬁcult. Further-
more, the outcomes of the ﬁrst two patients after a single dose is
unclear, as re-treatment after 10 and 15 months was likely prema-
ture. Current experience with MTLE patients suggests that seizure
cessation is usually delayed, with a response latency of at least
6 months and stabilization after 24 months [3,11,14–18,24]. There-
fore, while one could argue that we should have waited longer before
re-treating both of these patients, neither showed any of the afore-
mentioned radiographic effects of radiation at 10 and 12 months.
Taking such factors onto consideration, we have determined that
the initial 30 Gy was likely ineffective for the ﬁrst patient. At the
same time, the 37.5 Gy dose in Case 3 led to seizure freedom at the
cost of symptomatic headaches requiring corticosteroids. Therefore,Time before
recurrence [months]
Retreatment time
interval [months]
Retreatment
dose [Gy]
Seizure
outcome
Cerebral
edema
– 15 35.0 Class I No
1 10 40.0 Class I Yes
6 – – Class I Yes
6 C. Wu et al. / Epilepsy & Behavior Case Reports 1 (2013) 1–6the appropriate dosage may lie between 30 and 37.5 Gy. Once again, a
signiﬁcant amount of work must be completed to ﬁrst ﬁnd the ideal
dosage and subsequently to test the efﬁcacy of that dose.
5. Conclusion
Refractory epilepsy due to PVH may be successfully treated with
radiation therapy. These cases also suggest that intracranial electrode
recording does not provide any added value in patients with a PVH.
As long as the lesion was ablated, demonstrating an independent
zone of seizure onset in the temporal lobe neocortex did not preclude
seizure freedom. While the clinical response to SRS for epilepsy has a
reported latency of approximately 1–2 years, the importance of
radiation-induced vasogenic edema and role of MRS have also been
highlighted. While the upper limit of radiation is likely less than
37.5 Gy, further work is needed to deﬁne the optimal total dose and
to explore the possible application of fractionated radiotherapy as a
means to lower radiation toxicity to surrounding normal tissue.
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